These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7684214)

  • 21. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, combined with a immunopotentiator, LC9018, in Mycobacterium intracellulare infection induced in beige mice].
    Tomioka H; Sato K; Saito H; Hidaka T
    Kekkaku; 1993 Dec; 68(12):751-4. PubMed ID: 8301917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
    Saito H; Tomioka H; Sato K; Kawahara S; Hidaka T; Dekio S
    Tuber Lung Dis; 1995 Feb; 76(1):51-8. PubMed ID: 7718848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
    Klemens SP; Grossi MA; Cynamon MH
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2245-8. PubMed ID: 7840552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
    Mor N; Simon B; Heifets L
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice.
    Sano C; Shimizu T; Sato K; Kawauchi H; Kawahara S; Tomioka H
    Antimicrob Agents Chemother; 1999 Feb; 43(2):360-4. PubMed ID: 9925533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice.
    Shimizu T; Tomioka H; Sato K; Sano C; Akaki T; Dekio S; Yamada Y; Kamei T; Shibata H; Higashi N
    Antimicrob Agents Chemother; 1999 Mar; 43(3):514-9. PubMed ID: 10049260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Yokuinin on the therapeutic efficacy of a new benzoxazinorifamycin KRM-1648 against Mycobacterium avium infection.
    Shimizu T; Tomioka H; Sato K; Sano C; Yamada Y; Shibata H; Higashi N
    Int J Antimicrob Agents; 1999 Jan; 11(1):69-74. PubMed ID: 10075281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.
    Tomioka H; Saito H; Fujii K; Sato K; Hidaka T
    Antimicrob Agents Chemother; 1993 Jan; 37(1):67-70. PubMed ID: 8431020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages.
    Bermudez LE; Inderlied CB
    Microb Drug Resist; 1997; 3(3):277-82. PubMed ID: 9270999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of bacterial regrowth at the sites of infection in Mycobacterium avium complex-infected mice during treatment with chemotherapeutic agents].
    Sato K; Tomioka H; Maw WW; Saito H
    Kekkaku; 1995 Dec; 70(12):673-8. PubMed ID: 8551714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648.
    Tomioka H; Saito H
    Int J Lepr Other Mycobact Dis; 1993 Jun; 61(2):255-8. PubMed ID: 8371034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648.
    Fujii K; Saito H; Tomioka H; Mae T; Hosoe K
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1489-92. PubMed ID: 7492091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.
    Inderlied CB; Barbara-Burnham L; Wu M; Young LS; Bermudez LE
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1838-43. PubMed ID: 7986017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo activities of KRM-1648, a newly synthesized benzoxazinorifamycin, against Mycobacterium marinum.
    Yamamoto Y; Saito H; Tomioka H; Sato K; Yamane T; Yamashita K; Hosoe K; Hidaka T
    Zentralbl Bakteriol; 1992 Jul; 277(2):204-9. PubMed ID: 1520979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
    Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
    Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
    Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F
    Antimicrob Agents Chemother; 1996 Feb; 40(2):426-8. PubMed ID: 8834891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648.
    Dhople AM
    Arzneimittelforschung; 2001; 51(6):501-5. PubMed ID: 11455683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.
    Klemens SP; Cynamon MH
    Antimicrob Agents Chemother; 1996 Feb; 40(2):298-301. PubMed ID: 8834869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.